Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

doi:10.1158/1078-0432.CCR-19-3507

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2020

Barroso-Sousa Romualdo, Keenan Tanya E, Pernas Sonia, Exman Pedro, Jain Esha, Garrido-Castro Ana C, Hughes Melissa, Bychkovsky Brittany, Umeton Renato, Files Janet L, Lindeman Neal I, MacConaill Laura E, Hodi F Stephen, Krop Ian E, Dillon Deborah, Winer Eric P, Wagle Nikhil, Lin Nancy U, Mittendorf Elizabeth A, Van Allen Eliezer M, Tolaney Sara M

Abstract excerpt

PURPOSE: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and PTEN alterations, defined as nonsynonymous mutations or 1 or 2 copy deletions, were associated with clinical benefit to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Programmed Cell Death 1 Receptor

Share to PTEN Phosphohydrolase

Share to Survival Rate

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32019858
DOI: 10.1158/1078-0432.CCR-19-3507
PMCID: PMC7269810

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.PMID 32019858Read ↗

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.Semantic proximity Read ↗

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.Semantic proximity Read ↗

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.Semantic proximity Read ↗

The Correlation of PD-L1 Expression in Metaplastic BreastCancers with Clinical-Pathological Features and PrognosisSemantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancerSemantic proximity Read ↗

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read ↗

The Predictive Effect of Tumor Mutation Burden on prognosis in Breast cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breastSemantic proximity Read ↗

Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.